Divalproex Sodium Tablet, Extended Release
Product Images NDC 65162-755

6 FDA label images from Amneal Pharmaceuticals Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 65162-755). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Structure (Divalproex Sodium Extended Release Tablets Usp 1)

Structure (Divalproex Sodium Extended Release Tablets Usp 1)
Chemical structure of Divalproex Sodium showing the molecular arrangement with sodium ion and organic groups.*
FDA Label Image

Figure 1 (Divalproex Sodium Extended Release Tablets Usp 2)

Figure 1 (Divalproex Sodium Extended Release Tablets Usp 2)
A line graph comparing the percentage reduction in CPS rate between Divalproex Sodium (solid line) and placebo (dashed line) across the percentage of patients, illustrating patient response with axes labeled from 0 to 100% for patients and -100% to 100% for reduction rate, with improvement and worsening indicated.*
FDA Label Image

Figure 2 (Divalproex Sodium Extended Release Tablets Usp 3)

Figure 2 (Divalproex Sodium Extended Release Tablets Usp 3)
A cumulative percentage plot comparing high dose and low dose Divalproex Sodium. The vertical axis shows the percentage reduction in CPS rate, ranging from -100% (worsening) to 100% (improvement). The horizontal axis indicates the percentage of patients from 0 to 100%.*
FDA Label Image

Figure 3 (Divalproex Sodium Extended Release Tablets Usp 4)

Figure 3 (Divalproex Sodium Extended Release Tablets Usp 4)
A bar graph comparing placebo to Divalproex Sodium Extended Release. The vertical axis appears to show a numerical scale from 0.0 to 1.2. The placebo bar is lower, marked at 0.6, while the Divalproex Sodium Extended Release bar is higher at 1.2, with a significance marker indicating p=0.006.*
FDA Label Image

250 mg 100 Count (Divalproex Sodium Extended Release Tablets Usp 5)

250 mg 100 Count (Divalproex Sodium Extended Release Tablets Usp 5)
Label for Divalproex Sodium Extended-release Tablets, USP, 250 mg strength. The label shows the dosage form as extended-release tablets, quantity of 100 tablets, and highlights that dosing is once daily. It includes directions for pharmacists to dispense the medication guide. The manufacturer is Amneal Pharmaceuticals LLC. Storage instructions and a QR code linking to the medication guide are also visible.*
FDA Label Image

500 mg 100 Count (Divalproex Sodium Extended Release Tablets Usp 6)

500 mg 100 Count (Divalproex Sodium Extended Release Tablets Usp 6)
Label for Divalproex Sodium Extended-release Tablets, USP, 500 mg strength, oral extended-release tablets. The label indicates once-daily dosing and contains 100 tablets. It includes manufacturer details for Amneal Pharmaceuticals LLC and safety storage instructions. The Amneal logo is displayed prominently in the bottom left corner.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.